Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FRTXNASDAQ:GTBPNASDAQ:PBLANASDAQ:PRTG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsGTBPGT Biopharma$3.05+3.7%$2.54$1.72▼$4.10$7.89M1.37246,251 shs17,991 shsPBLAPanbela Therapeutics$0.23+1.2%$0.27$0.20▼$0.47$1.14M1.3518,550 shs26,922 shsPRTGPortage Biotech$5.56+0.4%$8.15$2.10▼$23.01$5.83M0.34983,454 shs8,578 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%-0.04%GTBPGT Biopharma0.00%+7.39%+14.23%+22.00%+2.01%PBLAPanbela Therapeutics0.00%-21.77%-4.36%-29.52%-38.24%PRTGPortage Biotech0.00%-7.18%-32.61%+33.98%-0.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGTBPGT Biopharma1.5602 of 5 stars3.82.00.00.00.60.00.6PBLAPanbela Therapeutics0.045 of 5 stars0.03.00.00.00.00.00.0PRTGPortage Biotech0.1628 of 5 stars0.04.00.00.00.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00260.66% UpsidePBLAPanbela Therapeutics 2.00HoldN/AN/APRTGPortage Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56GTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/APBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/APRTGPortage BiotechN/AN/A$8.06 per share0.69$3.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AGTBPGT Biopharma-$13.16M-$5.69N/AN/AN/AN/A-1,033.08%-223.20%8/13/2025 (Estimated)PBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%8/11/2025 (Estimated)PRTGPortage Biotech-$75.34M-$41.65N/A∞N/AN/A-342.34%-196.47%8/13/2025 (Estimated)Latest PBLA, GTBP, PRTG, and FRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/APRTGPortage BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFRTXFresh Tracks TherapeuticsN/AN/AN/AGTBPGT BiopharmaN/A0.730.73PBLAPanbela TherapeuticsN/A0.260.26PRTGPortage BiotechN/A3.083.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFRTXFresh Tracks Therapeutics25.04%GTBPGT Biopharma8.15%PBLAPanbela Therapeutics4.37%PRTGPortage Biotech13.36%Insider OwnershipCompanyInsider OwnershipFRTXFresh Tracks Therapeutics0.23%GTBPGT Biopharma3.40%PBLAPanbela Therapeutics0.01%PRTGPortage BiotechN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableGTBPGT Biopharma82.59 million2.50 millionNo DataPBLAPanbela Therapeutics64.86 million4.86 millionNot OptionablePRTGPortage Biotech61.05 millionN/AOptionablePBLA, GTBP, PRTG, and FRTX HeadlinesRecent News About These CompaniesPortage Biotech (NASDAQ:PRTG) vs. Hypera (OTCMKTS:HYPMY) Head to Head ContrastJune 16, 2025 | americanbankingnews.comPortage Biotech acquires stake in Compedica for $5 millionJune 10, 2025 | investing.comPortage Biotech and Compedica Forge Strategic Alliance with Stock ExchangeJune 9, 2025 | tipranks.comPortage Biotech Inc. Enters Subscription Agreement with Compedica Holdings Limited for Strategic Equity InvestmentJune 9, 2025 | quiverquant.comPortage Biotech and Compedica Stock-for-Stock ExchangeJune 9, 2025 | globenewswire.comPortage Biotech Shares Rise on Confirmatory Trial Results, Plans for Human TrialApril 28, 2025 | marketwatch.comPortage Biotech stock soars on promising preclinical resultsApril 28, 2025 | za.investing.comPortage Biotech Stock Surges On New Preclinical Data In Mesothelioma Trial: Retail Gets More BullishApril 28, 2025 | msn.comPortage Biotech Inc. Reports Positive Preclinical Efficacy Data for PORT-7 at AACR Annual Meeting 2025April 28, 2025 | quiverquant.comPortage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7April 28, 2025 | globenewswire.comInsider Stock Buying Reaches US$2.15m On Portage BiotechApril 26, 2025 | finance.yahoo.comPortage Biotech Inc. Common Stock (PRTG) Pre-MarketMarch 30, 2025 | nasdaq.comPortage Biotech presents preclinical data for PORT-7March 28, 2025 | markets.businessinsider.comPortage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment TrialMarch 27, 2025 | marketwatch.comPortage Biotech stock soars on promising preclinical dataMarch 27, 2025 | investing.comPortage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7March 27, 2025 | markets.businessinsider.comPortage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6March 14, 2025 | nasdaq.comPortage Biotech Inc. Announces New Director Compensation Plan and Stock Option GrantsMarch 13, 2025 | tipranks.comPortage resumes enrollment in final cohort of dose escalation for ADPORT-601March 12, 2025 | markets.businessinsider.comPortage Biotech Resumes Key Trial Enrollment, Advances Innovative Immunotherapy ApproachMarch 12, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBLA, GTBP, PRTG, and FRTX Company DescriptionsFresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.GT Biopharma NASDAQ:GTBP$3.05 +0.11 (+3.74%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.04 -0.01 (-0.33%) As of 06/20/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Panbela Therapeutics NASDAQ:PBLA$0.23 +0.00 (+1.16%) As of 06/20/2025 03:37 PM EasternPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.Portage Biotech NASDAQ:PRTG$5.56 +0.02 (+0.36%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$5.79 +0.23 (+4.14%) As of 06/20/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
